BPTH(Delisted)
Bio-Path Holdings·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BPTH
Bio-Path Holdings, Inc.
A biotechnology company that develops a portfolio of targeted nucleic acid cancer drugs
4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401
--
Bio-path Holdings, Inc. The company was founded on May 10, 2007. The company is a clinical and preclinical stage RNAi nanoparticle drug development company focused on oncology, utilizing a new technology for whole-body delivery for target-specific protein inhibition of any gene product that is overexpressed in disease.
Company Financials
EPS
BPTH has released its 2024 Q4 earnings. EPS was reported at -0.07, versus the expected -0.37, beating expectations. The chart below visualizes how BPTH has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
